Home > Resources > Whitepapers > Bio-Inert HPLC Analysis of Nucleotides

Bio-Inert HPLC Analysis of Nucleotides

July 15, 2019

Phosphorylated compounds such as nucleotides are known to interact with stainless steel components leading to recovery issues in HPLC and LC/MS. This Application Note describes the analysis of nucleotides using the Agilent 1260 Infinity II Bio-Inert LC System and a PEEK-lined Agilent InfinityLab Poroshell 120 HILIC-Z column. The fully inert flowpath, governed by the setup, leads to substantially improved recoveries of these challenging phosphorylated solutes

Spotlight

Pharming Group N.V.

Pharming group N.V. is committed to the development of innovative products for the treatment of unmet medical needs. By developing specialized therapeutic products Pharming offers alternative treatment options for its patients, improving their quality of life and saving lives.

OTHER WHITEPAPERS

A Review of RNA Analysis using the Agilent AutomatedElectrophoresis Portfolio

whitePaper | July 15, 2022

Good-quality RNA is crucial to the success of many downstream applications, including qPCR, microarray analysis, and RNA sequencing. Agilent automated

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

whitePaper | March 22, 2023

If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.